Last reviewed · How we verify

Myocardial Reinfarction Prevention — Treatment Landscape & Competitive Intelligence

Myocardial Reinfarction Prevention (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Myocardial Reinfarction Prevention, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Eliquis apixaban Bristol-Myers Squibb Factor Xa inhibitor Factor Xa (FXa) 2012-01-01
Effient PRASUGREL Cosette P2Y12 Platelet Inhibitor P2Y purinoceptor 12 2009-01-01
Plavix clopidogrel Generic (originally Sanofi/BMS) Thienopyridine antiplatelet agent Cytochrome P450 2B6, P2Y purinoceptor 12, Sodium-dependent serotonin transporter 1997-11-17
Mevacor LOVASTATIN Merck & Co. HMG-CoA Reductase Inhibitor 3-hydroxy-3-methylglutaryl-coenzyme A reductase 1987-01-01
Lopressor metoprolol Generic (originally Ciba-Geigy/Novartis) Beta-1 selective blocker Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, 5-hydroxytryptamine receptor 1A 1978-08-07
Inderal propranolol Generic (originally ICI/AstraZeneca) Non-selective beta-blocker Nuclear receptor subfamily 2 group E member 1, 5-hydroxytryptamine receptor 6, Cytochrome P450 1A2 1967-11-13
Coumadin warfarin Generic (originally Wisconsin Alumni Research Foundation) Vitamin K antagonist (anticoagulant) Vitamin K epoxide reductase complex subunit 1-like protein 1, Cytochrome P450 2C9, Proprotein convertase subtilisin/kexin type 7 1954-01-01
Myoinositol Myoinositol University of Colorado, Denver
Brilinta Brilinta AstraZeneca Equilibrative nucleoside transporter 1, P2Y purinoceptor 12, P2Y purinoceptor 12
Brilinta ticagrelor AstraZeneca P2Y12 Platelet Inhibitor [EPC] Equilibrative nucleoside transporter 1, P2Y purinoceptor 12, P2Y purinoceptor 12

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. AstraZeneca · 2 drugs in Myocardial Reinfarction Prevention
  2. Bristol-Myers Squibb · 1 drug in Myocardial Reinfarction Prevention
  3. Cosette · 1 drug in Myocardial Reinfarction Prevention
  4. Generic (originally Ciba-Geigy/Novartis) · 1 drug in Myocardial Reinfarction Prevention
  5. Generic (originally ICI/AstraZeneca) · 1 drug in Myocardial Reinfarction Prevention
  6. Generic (originally Sanofi/BMS) · 1 drug in Myocardial Reinfarction Prevention
  7. Generic (originally Wisconsin Alumni Research Foundation) · 1 drug in Myocardial Reinfarction Prevention
  8. Merck & Co. · 1 drug in Myocardial Reinfarction Prevention
  9. · 1 drug in Myocardial Reinfarction Prevention
  10. University of Colorado, Denver · 1 drug in Myocardial Reinfarction Prevention

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Myocardial Reinfarction Prevention:

Cite this brief

Drug Landscape (2026). Myocardial Reinfarction Prevention — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/myocardial-reinfarction-prevention. Accessed 2026-06-11.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing